Carbogen Amcis expands operations in Bubendorf
The acquired multi-story building is divided into laboratory, production, storage and office areas and provides a set of cleanroom GMP-compliant suites.
Carbogen Amcis, a Swiss-based company offering process development and manufacturing of APIs to the pharmaceutical industry, has announced the extension of its operations in Bubendorf.
On 26 May 2016, Carbogen Amcis undersigned the acquisition of the land and buildings of GEA Pharma Systems AG in Bubendorf, Hauptstrasse 145. The acquisition, which is close to the company's current headquarters, will become effective on 1 January 2017.
Located on 5200 m² of land, the 3360 m² multi-story building is divided into laboratory, production, storage and office areas and provides a set of cleanroom GMP-compliant suites. The company is planning modification work to adapt the building to its specific requirements and convert more of the facility into GMP operations areas.
“The immediate proximity to our current headquarters and our larger scale production site in Bubendorf, Switzerland, is ideal. It will allow us to significantly extend our laboratory capacity for highly potent development and small scale production as well as analytical support,” said Stephan Fritschi, Vice-President Operations at Carbogen Amcis. “Operations are scheduled to expand into the new building in 2017.”
“In the last couple of years we have experienced a significant and continuous increase in customers’ demand for additional capacity, including demand for labs and small-scale development,” said Mr Janmejay Vyas, Chairman of the Dishman Group of Companies. “This acquisition is targeted to support our business growth and company expansion. It will allow Carbogen Amcis to keep its position as an industry leader and outsourcing partner for complex highly potent APIs and ADCs.”
“I am delighted that we are able to extend our operations in Bubendorf to fulfil our customer needs and their growing expectations,” Commented Mark Griffiths, Global CEO of Carbogen Amcis and the Dishman Group. “Moreover, this facility will bring new opportunities to further enhance our capabilities and capacities. In the near future, the company plans to introduce a number of additional capabilities including, but not limited to, commercial manufacture of ADCs and additional Cat 4 (ng OEL) development capacity. The new facility is closely located with our current Carbogen Amcis Headquarters in Bubendorf and as such enables us to leverage the existing support network to the new site."
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance